Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.
You may also be interested in...
As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.
Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.
The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."